Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 March 2019

Abstract and Keywords

In this chapter, we review the evidence from double-blind, randomized, placebo-controlled trials for the pharmacotherapy of generalized anxiety disorder (GAD). Selective serotonin reuptake inhibitors are considered first-line medications in the treatment of GAD. There is also evidence for the use of serotonin-norepinephrine reuptake inhibitors. While benzodiazepines have the advantage of rapid onset of action, they lack antidepressant effects and may result in dependence. While there is evidence for the efficacy of the tricyclics and monoamine oxidase inhibitors in anxiety and depressive disorders, their use is limited by their less favorable side-effect profile. Other medication classes that are utilized in GAD include 5-HT1A agonists and anticonvulsants, and recent studies have investigated atypical antipsychotics as adjunctive medications in GAD.

Keywords: anticonvulsant, antidepressant, anxiety, benzodiazepine, experimental therapeutics, pharmacotherapy, serotonin reuptake inhibitor

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.